Values as of: 2024-10-04
COMMON STOCK | Medical Devices |
Last Closing
USD 15.16Change
0.00 (0.00)%Market Cap
USD 13.18BVolume
N/AAnalyst Target
USD 48.00Verdict
Verdict
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Company Website : https://www.smith-nephew.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ABT | Abbott Laboratories |
+0.41 (+0.37%) |
USD 195.27B |
| MDT | Medtronic PLC |
+0.49 (+0.56%) |
USD 114.31B |
| STE | STERIS plc |
-1.84 (-0.79%) |
USD 23.57B |
| ZBH | Zimmer Biomet Holdings Inc |
+0.49 (+0.47%) |
USD 22.04B |
| SNN | Smith & Nephew SNATS Inc |
-0.13 (-0.43%) |
USD 13.32B |
| GMED | Globus Medical |
+0.62 (+0.89%) |
USD 9.55B |
| BIO | Bio-Rad Laboratories Inc |
+6.61 (+1.96%) |
USD 9.53B |
| BIO-B | Bio-Rad Laboratories Inc |
N/A |
USD 9.38B |
| PEN | Penumbra Inc |
-0.26 (-0.13%) |
USD 7.80B |
| GKOS | Glaukos Corp |
+4.18 (+3.30%) |
USD 7.05B |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 9.38% | 66% | D+ | 54% | F | ||
| Dividend Return | 2.71% | 88% | B+ | 49% | F | ||
| Total Return | 12.09% | 66% | D+ | 54% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 28.91% | 66% | D+ | 71% | C- | ||
| Dividend Return | 3.19% | 88% | B+ | 44% | F | ||
| Total Return | 32.10% | 66% | D+ | 70% | C- | ||
| Trailing 5 Years | |||||||
| Capital Gain | -32.92% | 28% | F | 14% | F | ||
| Dividend Return | 7.27% | 67% | D+ | 21% | F | ||
| Total Return | -25.65% | 32% | F | 13% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -9.58% | N/A | N/A | 23% | F | ||
| Dividend Return | -7.54% | N/A | N/A | 23% | F | ||
| Total Return | 2.04% | N/A | N/A | 42% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 15.21% | N/A | N/A | 92% | A | ||
| Risk Adjusted Return | -49.60% | N/A | N/A | 15% | F | ||
| Market Capitalization | 13.18B | 82% | B | 88% | B+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
